Characteristics of clinical trials to support approval of orphan drugs for neurological disorders by the Japanese regulatory agency

被引：0
|
作者：
Nakamura, H. [1 ]
Takeda, S. [2 ]
Iwasaki, M. [3 ]
机构：
[1] Natl Ctr Neurol & Psychiat, Translat Med Ctr, Kodaira, Tokyo, Japan
[2] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Kodaira, Tokyo, Japan
[3] Univ Yamanashi, Dept Clin Res, Interdisciplinary Grad Sch Med & Engn, Kofu, Yamanashi, Japan
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2017年 / 381卷
关键词：
D O I：
10.1016/j.jns.2017.08.2385
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2354
引用
收藏
页码：847 / 847
页数：1
相关论文
共 50 条
  • [1] Identification of approval conditions for orphan drugs for neurological disorders by the Japanese regulatory agency
    Nakamura, Harumasa
    Takeda, Shin'ichi
    Iwasaki, Masaru
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (07): : 441 - 447
  • [2] Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
    Kesselheim, Aaron S.
    Myers, Jessica A.
    Avorn, Jerry
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2320 - 2326
  • [3] Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency
    Maeda, H.
    Kurokawa, T.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 211 - 216
  • [4] Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan
    Nakayama, Hiroki
    Tsukamoto, Katsura
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 702 - 708
  • [5] Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan
    Hiroki Nakayama
    Katsura Tsukamoto
    Investigational New Drugs, 2018, 36 : 702 - 708
  • [6] Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan
    Akihiro Ishiguro
    Satomi Yagi
    Yoshiaki Uyama
    Journal of Human Genetics, 2013, 58 : 313 - 316
  • [7] Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan
    Ishiguro, Akihiro
    Yagi, Satomi
    Uyama, Yoshiaki
    JOURNAL OF HUMAN GENETICS, 2013, 58 (06) : 313 - 316
  • [8] Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending
    Michaeli, D. T.
    Michaeli, C. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S927 - S927
  • [9] Clinical Trials of Orphan Drugs for Cancer Reply
    Kesselheim, Aaron S.
    Avorn, Jerry
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (14): : 1545 - 1546
  • [10] Biases in clinical trials performed for regulatory approval
    Jan S. Krouwer
    Accreditation and Quality Assurance, 2015, 20 : 437 - 439
12345